How we publish

Editorial, clinical review and corrections policy

A transparent standard for content about aesthetic treatment documentation, clinical workflows and the Aesthetic Pass product.

Published and last reviewed

1. Publisher and purpose

drylabs GmbH publishes Aesthetic Pass resources to help qualified providers and clinic teams understand documentation workflows, evaluate software and use the current product responsibly. drylabs GmbH also sells Aesthetic Pass. We disclose that commercial role and do not present product-led material as independent journalism.

2. Authorship and clinical review

The Aesthetic Pass Editorial or Product Team prepares product, workflow and operational content. A named clinical reviewer checks clinical terminology, safety framing, the separation between record-keeping and treatment decisions, and the accuracy of statements about the current product.

The current clinical reviewer is Dr. Adi Zoabi, MD, a Germany-based physician with completed specialty training in dermatology, aesthetic medicine experience and a BSc in Computer Science.

3. Evidence and product verification

  • Primary sources first: current regulator, legislation, professional-body, prescribing-information and standards sources are preferred for health, safety and legal context.
  • Current product evidence: capability claims are checked against the shipped workflow, code-backed product contract or a controlled test using fictional or anonymised demonstration data.
  • Boundaries stay visible: we state material non-capabilities and do not convert documentation software into a diagnosis, dose recommendation, product-authenticity guarantee or universal compliance claim.
  • Jurisdiction matters: legal or professional requirements are dated and scoped. Content is not a substitute for qualified legal, privacy or medical advice for a particular practice.

4. Commercial disclosure and comparisons

The clinical reviewer is also a founder, Medical Director and Lead Software Developer of Aesthetic Pass. This conflict is disclosed on his profile and in relevant product-led content. Comparisons must use dated, attributable evidence, distinguish different software categories fairly and avoid unverifiable โ€œbest,โ€ market-leader or outcome claims.

5. Updates, corrections and revision dates

Every material resource displays a published or updated date. We review content when the product workflow changes, a primary source changes, a factual error is reported or search demand reveals that a page is misleadingly scoped. Material corrections update the review date and should preserve a clear explanation when the previous wording could affect clinical or purchasing decisions.

To request a correction, use the contact page and include the page URL, disputed statement and supporting source. Do not send patient information.

6. Localisation and privacy

Translations must preserve clinical boundaries, product names, source meaning and disclosure. New source copy is not released to a translated route until its localisation contract passes. Public content and analytics must never expose patient names, passport tokens, treatment records or other clinical data.